Gilead Sciences’s new Hepatitis C drug, Sovaldi, shocked patients, payers and politicians with it’s skyrocket pricing, but a new report suggests this may not be an exception to the rule. According to data from EvaluatePharma, it’s a reflection of a trend that has been going on for 5 years now. Read more here. (Source: Eric Palmer, FiercePharma, 9/25/14).
You are here: / / Could Sovaldi’s Nosebleed Pricing Be The New Norm?